PDCD1LG2 and colorectal cancer: Masugi et al. found a negative correlation between PDCD1LG2 expression and Crohn’s-like lymphoid response in colorectal cancer, suggesting that PDCD1LG2 positive tumor cells may be involved in inhibiting the development of tertiary lymphoid tissues during colorectal carcinogenesis [29].We performed susceptibility-related analysis and found that differential expression of LINC02154 affected the sensitivity of pazopanib, sorafenib, sunitinib, and temsirolimus.